Related Experiment Videos

Characterization of MBT-2 tumour cell "variant" resistant to tumour necrosis factor

S A Kadhim1, J Y Wang, B McLean

  • 1Department of Surgery, University Hospital, University of Western Ontario, London, Canada.

Urological Research
|January 1, 1991
PubMed

Insights

Tumor necrosis factor (TNF) resistance in MBT-2 bladder cancer cells emerged after prolonged exposure. This resistance is linked to cell cycle changes, not genetic mutations, suggesting TNF

Area of Science:

  • Oncology
  • Immunology
  • Cell Biology

Background:

  • Previously, MBT-2 murine bladder tumors demonstrated sensitivity to tumor necrosis factor (TNF).
  • Prolonged in vitro exposure to TNF led to the emergence of a TNF-resistant MBT-2 variant cell population.
  • This in vitro observation correlated with the transient in vivo cytotoxic effect of TNF against MBT-2 tumors.

Purpose of the Study:

  • To delineate the phenotypic changes in MBT-2 cells associated with acquired TNF resistance.
  • To compare parent MBT-2 (MBT-2P) and TNF-resistant MBT-2R cells regarding TNF sensitivity, DNA profile, karyotype, and growth kinetics.

Main Methods:

  • In vitro sensitivity assays to TNF.
  • DNA profiling and karyotyping of parent and variant cells.
  • Assessment of in vitro growth kinetics.

Main Results:

  • Phenotypic characterization of MBT-2 cells revealed differences associated with TNF resistance.
  • Comparison between MBT-2P and MBT-2R cells highlighted variations in TNF sensitivity and growth characteristics.
  • DNA indices and karyotypes of MBT-2R cells remained unaltered compared to MBT-2P cells.

Conclusions:

  • Acquisition of TNF resistance in MBT-2 cells may be attributed to cell cycle derangements and altered in vitro growth characteristics.
  • The anti-tumor action of TNF is not mutagenic, as evidenced by the stable DNA indices and karyotypes in resistant cells.
  • Understanding these mechanisms is crucial for optimizing TNF-based cancer therapies.

Related Concept Videos